Skip to main content
CTIS.
EU
Conditions
IMPs
Countries
Sponsors
Sites
Trial Map
Safety
Transparency
Landscape
EN — English
BG — Български
CS — Čeština
DA — Dansk
DE — Deutsch
EL — Ελληνικά
ES — Español
ET — Eesti
FI — Suomi
FR — Français
GA — Gaeilge
HR — Hrvatski
HU — Magyar
IT — Italiano
LT — Lietuvių
LV — Latviešu
MT — Malti
NL — Nederlands
PL — Polski
PT — Português
RO — Română
SK — Slovenčina
SL — Slovenščina
SV — Svenska
NO — Norsk
CTIS.
EU
✕
Conditions
IMPs
Countries
Sponsors
Sites
Trial Map
Safety
Transparency
Landscape
Notice
This is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
CTIS.eu
›
Conditions
› Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
2 total trials
1 recruiting
Filter these 2 trials by phase, country, sponsor and more.
Open in Search →
The ENERGY 2 Study: A study to investigate if study drug INZ-701 increases survival in infants with ENPP1 Deficiency by preventing heart dys …
Recruiting
2024-512991-36-00
5
2024-10-24
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
Recruitment ended
2023-507382-26-00
5
2024-05-24
Showing 1–2 of 2 trials